Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Peripheral 1Esophageal Squamous Cell Carcinoma 1

Interventions

Specimen Handling 625pembrolizumab 606Magnetic Resonance Spectroscopy 550Carboplatin 448Cisplatin 396Cyclophosphamide 394Biopsy 371Paclitaxel 323Nivolumab 322Gemcitabine 317Radiotherapy 283Bevacizumab 242Dexamethasone 222fludarabine 213Docetaxel 198durvalumab 194Oxaliplatin 187venetoclax 186atezolizumab 179Fluorouracil 176Rituximab 175Pemetrexed 172Capecitabine 167Radiation 164Doxorubicin 164Radiosurgery 159Ipilimumab 145Etoposide 142Leucovorin 140Lenalidomide 138

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ivarmacitinib × 90 days × Clear all
NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06519526 2026-03-24

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Fudan University

Phase 2 Recruiting
25 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡